Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: May 21, 2022

Details for New Drug Application (NDA): 018841

✉ Email this page to a colleague

« Back to Dashboard

NDA 018841 describes DAYPRO, which is a drug marketed by Pfizer and is included in two NDAs. It is available from three suppliers. Additional details are available on the DAYPRO profile page.

The generic ingredient in DAYPRO is oxaprozin potassium. There are thirteen drug master file entries for this compound. Additional details are available on the oxaprozin potassium profile page.
Summary for 018841
Formulation / Manufacturing:see details
Pharmacology for NDA: 018841
Mechanism of Action Cyclooxygenase Inhibitors
Suppliers and Packaging for NDA: 018841
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DAYPRO oxaprozin TABLET;ORAL 018841 NDA Pfizer Laboratories Div Pfizer Inc 0025-1381 0025-1381-31 100 TABLET, FILM COATED in 1 BOTTLE (0025-1381-31)
DAYPRO oxaprozin TABLET;ORAL 018841 NDA PD-Rx Pharmaceuticals, Inc. 55289-453 55289-453-14 14 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55289-453-14)

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength600MG
Approval Date:Oct 29, 1992TE:ABRLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.